Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
Merck’s Acquisition of Eyebiotech
Johnson & Johnson’s Acquisition of Ambrx Biopharma
Cravath, Swaine & Moore is serving as legal counsel to Johnson & Johnson, while Skadden is serving as legal counsel to Ambrx Biopharma on the transaction....
Mirati Therapeutics’ Merger With Bristol Myers Squibb
Kirkland & Ellis LLP advised Bristol Myers Squibb, while Skadden, Arps, Slate, Meagher & Flom LLP advised Mirat on the deal. Bristol Myers Squibb (NYSE: BMY)...
Swedish Orphan Biovitrum’s Acquisition of CTI BioPharma
Skadden and Gibson, Dunn & Crutcher acted as legal advisor on the transaction. CTI BioPharma (Nasdaq: CTIC) (“CTI”) entered into a definitive agreement under which Swedish Orphan...
GSK’s Acquisition of BELLUS Health
Paul, Weiss, Rifkind, Wharton & Garrison LLP, and Stikeman Elliott LLP advised GSK, while Skadden, Arps, Slate, Meagher & Flom LLP, and Davies Ward Phillips &...
Pfizer’s Acquisition of Seagen
Wachtell, Lipton, Rosen & Katz is acting as Pfizer’s legal advisor. Sullivan & Cromwell is serving as Seagen’s Board of Directors legal advisor. Skadden is advising...
Vertex’s $320 Million Acquisition of ViaCyte
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
Halozyme Therapeutics’ Acquisition of Antares Pharma
Weil, Gotshal & Manges advised Halozyme, while Skadden, Arps, Slate, Meagher & Flom advised Antares Pharma on the deal. Fried Frank acted as counsel to BofA...
Alcon’s Acquisition of U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Skadden, Arps, Slate, Meagher & Flom LLP advised Alcon on the deal. Alcon, the global leader in eye care dedicated to helping people see brilliantly, has...